Newsroom

Press Contacts

Michelle Linn
Media
michelle@linndencom.com

News Releases

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

Boston, MA - June 10, 2025 - Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25...

View full release

Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model

May 15, 2025 -- Boston, MA -- Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, presented preclinical data demonstrating the potential of its tRNA therapy in Duchenne Muscular Dystrophy (...

View full release

Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

April 29, 2025 -- Boston, MA -- Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will present preclinical data supporting the potential of its tRNA therapy in Duchenne Muscular Dystrophy...

View full release